title: Enhanced immune response to DNA-based HPV16L1 vaccination by costimulatory molecule B7-2.
abstract: We have investigated whether co-injection of DNA encoding the costimulatory molecule B7-2 augments immune response to the major capsid protein L1 of the high-risk human papillomavirus type 16 (HPV16L1). While immunoglobulin G (IgG) specific to HPV16L1 was detected in sera from mice injected intramuscularly with pcDNA-L1 that encodes HPV16L1, a significantly increased level of IgG was found in sera from mice immunised with pcDNA-L1 in conjunction with pLXHDmB7-2 DNA. Levels of IgG in the anti-sera were correlated with the inhibitory activity of the murine erythrocyte hemagglutination caused by the virus-like particles (VLP) and the binding of VLP to HeLa cells. Moreover, splenic cells isolated from mice co-injected with pLXHDmB7-2 had stronger proliferation and more IFN-gamma producing T cells (CD4(+) and CD8(+)) when stimulated with HPV16 VLP compared with cells from mice that had received pcDNA-L1 alone and mice of the control groups. Furthermore, in footpad swelling test, mice co-immunised with pLXHDmB7-2 had greater skin thickness over those immunised with pcDNA-L1 alone or control mice. We conclude that co-injection of DNA encoding B7-2 can enhance both humoral and cellular immune responses elicited by DNA-based vaccination against HPV16 infection in mice.
authors.affiliation: Institute for Cancer Research, College of Life Science and Technology, Xi'an Jiaotong University, 710061, Xi'an, PR China.
authors.forename: Jin
authors.initials: J
authors.lastname: Zheng
authors.forename: Lusheng
authors.initials: L
authors.lastname: Si
authors.forename: Jianmin
authors.initials: J
authors.lastname: Song
authors.forename: Xiangle
authors.initials: X
authors.lastname: Sun
authors.forename: Jun
authors.initials: J
authors.lastname: Yu
authors.forename: Yili
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D015703:Antigens, CD / Q000009:adverse effects / Q000494:pharmacology*; D051940:B7-2 Antigen; D002455:Cell Division; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D005528:Foot / Q000473:pathology; D006367:HeLa Cells; D006384:Hemagglutination; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000276:immunology; D008562:Membrane Glycoproteins / Q000009:adverse effects / Q000494:pharmacology*; D051379:Mice; D027383:Papillomaviridae / Q000276:immunology*; D010957:Plasmids / Q000235:genetics; D013154:Spleen / Q000166:cytology; D013601:T-Lymphocytes / Q000276:immunology / Q000821:virology; D019444:Vaccines, DNA / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D051940:B7-2 Antigen; C497964:CD86 protein, human; C497965:Cd86 protein, mouse; D007074:Immunoglobulin G; D008562:Membrane Glycoproteins; D019444:Vaccines, DNA; D014765:Viral Vaccines